Location History:
- Buenos Aires, AR (US) (2013)
- Long Beach, CA (US) (2014)
Company Filing History:
2 out of 15,488 
1 out of 10 Years Active: 2013-2014
Title: The Innovative Contributions of Gustavo Helguera
Introduction
Gustavo Helguera is a notable inventor based in Long Beach, California. He has made significant contributions to the field of cancer treatment through his innovative research and development of monoclonal antibodies. With a total of two patents to his name, Helguera's work focuses on advancing therapeutic options for patients suffering from cancer.
Latest Patents
One of Helguera's latest patents involves the development of IgE antibodies for the treatment of cancer. This invention provides monoclonal IgE antibodies that comprise Fc epsilon constant regions and variable regions with at least one antigen binding region specific for a single epitope of a circulating tumor-associated antigen (TAA). The targeted epitope is not highly repetitive or is a non-repetitive epitope, making these antibodies particularly useful in treating cancer associated with tumor antigens, such as prostate-specific antigen (PSA). Another significant patent focuses on antibody fusion with IL-12 proteins that have disrupted heparin-binding activity. This invention includes polypeptides that link an antibody to a cytokine, with modified heparin binding regions that reduce the cytokine's ability to bind heparin compounds. These polypeptides have potential applications in treating cancer, inducing cell proliferation, and minimizing non-specific binding.
Career Highlights
Gustavo Helguera has worked with prestigious organizations, including the University of California and Quest Pharmatech, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Helguera has collaborated with notable colleagues, including Manuel L Penichet and Birgit Corinna Schultes. These partnerships have further enhanced his research and development efforts in the field of cancer treatment.
Conclusion
Gustavo Helguera's innovative work in developing monoclonal antibodies and cytokine fusions represents a significant advancement in cancer therapy. His contributions continue to pave the way for new treatment options that may improve patient outcomes.